Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML

Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA
Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML ( Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA )
7 Dec 2020

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020

Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
7 Dec 2020

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia

Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA
Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia ( Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA )
5 Dec 2020

PARP inhibitors in prostate cancer: A promise delivered

Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA
PARP inhibitors in prostate cancer: A promise delivered ( Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA )
1 Dec 2020

Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells

Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom
Targeting a KRAS neoantigen peptide vaccine to DNGR-1  dendritic cells ( Dr Rachel Ambler - The Francis Crick Institute, London, United Kingdom )
27 Nov 2020

OncoAlert and ecancer weekly roundup for November 15 - 21, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for November 15 - 21, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
27 Nov 2020

Clinical genomic testing in prostate cancer

Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA
Clinical genomic testing in prostate cancer ( Laurie M Connors - Vanderbilt University School of Nursing, Nashville, USA )
24 Nov 2020

PARP inhibitors for prostate cancer - Nurse's view

Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA
PARP inhibitors for prostate cancer - Nurse's view ( Laurie M. Connors - Vanderbilt University School of Nursing, Nashville, USA )
24 Nov 2020

Predictors of efficacy in patients with HR positive/HER2 negative ABC: Subgroup analyses of PALOMA-3

Prof Hope Rugo - University of California, San Francisco, USA
Predictors of efficacy in patients with HR positive/HER2 negative ABC: Subgroup analyses of PALOMA-3 ( Prof Hope Rugo - University of California, San Francisco, USA )
23 Nov 2020

OncoAlert and ecancer weekly roundup for November 8 - 14, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for November 8 - 14, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Nov 2020

Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor

Dr Filip Janku - The University of Texas MD Anderson Cancer Center USA
Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor ( Dr Filip Janku - The University of Texas MD Anderson Cancer Center USA )
17 Nov 2020